Goldman Sachs
RXRX icon

Goldman Sachs’s Recursion Pharmaceuticals RXRX Stock Holding History

Goldman Sachs’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-87,700
Closed -$593K – 6363
2024
Q4 		$593K Hold
87,700
– – ﹤0.01% 5146
2024
Q3 		$578K Buy
+87,700
New +$629K ﹤0.01% 4968

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

Goldman Sachs's RXRX Position: Q1 2026 in Review

Goldman Sachs increased its Recursion Pharmaceuticals (RXRX) stake by 176% in Q1 2026, buying an estimated $14.9M and bringing the position to 6,065,661 shares worth $18.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2495.

Goldman Sachs first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Goldman Sachs held 6,065,661 shares of Recursion Pharmaceuticals worth $18.6M as of Q1 2026.
  • Goldman Sachs bought 3,864,219 Recursion Pharmaceuticals shares in Q1 2026, an estimated $14.9M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2495 holding.
  • Goldman Sachs first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.